Fig. 5

Validation of the prognostic performance of BCRFS-related CAF signature using GSE70769 and TCGA datasets. A, B ROC analysis showed that the AUCs of BCRFS-related CAF signature in predicting the 1-, 2-, and 3- year survival of patients with prostate cancer based on GSE70769 and TCGA datasets. C, D Kaplan–Meier survival curve analysis showed the survival of high‐risk and low‐risk patient cohorts divided by BCRFS-related CAF signature based on GSE70769 and TCGA datasets. CAF: cancer-associated fibroblast; BCRFS: biochemical recurrence-free survival; ROC: receiver operating characteristic; AUC: areas under the ROC curve